[artículo] 
inJournal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 21-26

Título :	Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications
Tipo de documento:	texto impreso
Autores:	Adel Wassef, Autor ; Nadir G. Hafiz, Autor ; Delilah Hampton, Autor
Fecha de publicación:	2023
Artículo en la página:	pp. 21-26
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Antipsicóticos, Farmacoterapia, Haloperidol, Hospitalización, Esquizofrenia.
Resumen:	Divalproex sodium has been approved for use in treating bipolar disorder. Its usefulness in schizophrenia has yet to be adequately assessed. Three days after initiating haloperidol treatment, patients who were hospitalized for an acute exacerbation of schizophrenia received either valproate augmentation (early-augmentation group) or continued to receive haloperidol alone (no-augmentation group).
Link:	./index.php?lvl=notice_display&id=31133

[artículo] Divalproex sodium augmentation of haloperidol in hospitalized patients with schizophrenia: clinical and economic implications [texto impreso] / Adel Wassef, Autor ; Nadir G. Hafiz, Autor ; Delilah Hampton, Autor . - 2023 . - pp. 21-26.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Journal of Clinical Psychopharmacology > Año 2001 - Vol. 21 - No. 1 (Febrero) . - pp. 21-26

Palabras clave:	Antipsicóticos, Farmacoterapia, Haloperidol, Hospitalización, Esquizofrenia.
Resumen:	Divalproex sodium has been approved for use in treating bipolar disorder. Its usefulness in schizophrenia has yet to be adequately assessed. Three days after initiating haloperidol treatment, patients who were hospitalized for an acute exacerbation of schizophrenia received either valproate augmentation (early-augmentation group) or continued to receive haloperidol alone (no-augmentation group).
Link:	./index.php?lvl=notice_display&id=31133